The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Mohammed - presume you mean this one published today with a mention of GDR:
Small-cap healthcare stocks outperform, but can the momentum be maintained? -
https://www.proactiveinvestors.co.uk/companies/news/926608/small-cap-healthcare-stocks-outperform-but-can-the-momentum-be-maintained-926608.html
They've updated Twitter as well with a link to 360DX:
https://twitter.com/genedriveplc/status/1291738879163346947
https://www.360dx.com/pcr/genedrive-beckman-coulter-life-sciences-partner-automated-pcr-testing-sars-cov-2?utm_source=addthis_shares#.Xy1g-e46Hmc.twitter
WHO 4th August update - In process
https://www.who.int/diagnostics_laboratory/200804_eul_covid19_ivd_update.pdf?ua=1
Buy - 13:43:38 55.00 1,600,000 880.00k
https://www.expressandstar.com/news/uk-news/2020/07/22/rapid-covid-19-test-trialled-in-care-homes/
Second RNS link (hopefully)
https://polaris.brighterir.com/public/genedrive/news/rns/story/w11m74w/export
ODX/Mologic test was developed with Liverpool School of Tropical Medicine who (according to article dated 12/3/20) are also working on GDR's POC test "The second test is being developed with industrial partners Genedrive, with whom we have submitted grant applications based upon prototype tests designed at LSTM and transferred to Genedrive’s portable PCR device. This test may help diagnose individuals outside of central referral systems, as even in Europe we cannot keep up with the huge demand for diagnosis tests."
https://www.lstmed.ac.uk/news-events/news/lstm-researchers-work-on-new-diagnostics-for-covid-19
LSTM is also linked with The Centre of Excellence in Infectious Diseases Research Innovations (a partnership between LSTM and the University of Liverpool, which develops relationships between industry and academia) who are in collaboration with the GHIT Fund among others.
http://www.ceidr.org.uk/collaborations
https://polaris.brighterir.com/public/genedrive/news/rns/story/w68ykgr/export
Genedrive plc (AIM: GDR) confirms that in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, as at 30 June 2020 the Company's issued share capital comprised 51,986,071 ordinary shares with voting rights ('Shares'). No Shares are held in Treasury. As such, the number of Shares with voting rights is 51,986,071.
This figure may be used by shareholders (and others with notifiable obligations) as their denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Apologies, should have added text:
'Genedrive moves to positive cash position as Global Health Investment Fund converts 2014 loan into equity with additional orderly marketing agreement. Following completion, Genedrive will have gross cash balances of £8.6mln and debt of £2.6mln https://lnkd.in/d9xH6iX'
@grim prob meant this update re today's RNS:
https://www.linkedin.com/company/genedrive-plc/
Linkedin update as well re testing helping countries.
'Two things are immediately evident: (i) countries that do lots of testing can, with other measures, start to bring things under control, and (ii) countries that have escalating COVID-19 cases are not testing enough and also must do more to help reduce transmission.'
https://www.linkedin.com/company/genedrive-plc/